Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer Excellence Forum

Non-Small Cell Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Kristin Higgins, MD, Winship Cancer Institute, GA
Videos
SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases
10/15/2022
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an...
10/15/2022
Oncology
Nasser Altorki, MD, Weill Cornell Medical College
Videos
Adjuvant Checkpoint Inhibitors in Resectable NSCLC
10/15/2022
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his...
10/15/2022
Oncology
Pasi Jänne, MD, Dana-Farber Cancer Institute
Videos
Trastuzumab Deruxtecan for HER2-Mutant Non-Small Cell Lung Cancer
09/21/2022
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights...
09/21/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania
Videos
Is There a Role for Tumor Treatment Fields in Advanced NSCLC?
09/21/2022
Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/21/2022
Oncology
Hossein Borghaei, DO
Debates and Roundtables
Roundtable Highlight: Dr Borghaei Shares Concerns of Chemo, Immunotherapy Combos for Patients with KRAS Mutations in NSCLC
01/10/2022
In this excerpt from our Roundtable titled, “Melina Marmarelis, MD, and Colleagues Talk Treatment of KRAS G12C NSCLC,” Dr Borghaei emphasizes the importance of weighing the risks and benefits of combining targeted therapies for patients with...
In this excerpt from our Roundtable titled, “Melina Marmarelis, MD, and Colleagues Talk Treatment of KRAS G12C NSCLC,” Dr Borghaei emphasizes the importance of weighing the risks and benefits of combining targeted therapies for patients with...
In this excerpt from our...
01/10/2022
Oncology
Dr Sun, Dr Borghaei
Debates and Roundtables
Roundtable Highlight: Dr Borghaei, Dr Sun Support Next-Gen Liquid Biopsy Testing to Detect KRAS Mutations in NSCLC
01/07/2022
In this featured virtual roundtable highlight, Lova Sun, MD and Hossein Borghaei, DO share optimal testing practices for the detection of KRAS G12C sensitive mutations in patients with non-small-cell lung cancer.
In this featured virtual roundtable highlight, Lova Sun, MD and Hossein Borghaei, DO share optimal testing practices for the detection of KRAS G12C sensitive mutations in patients with non-small-cell lung cancer.
In this featured virtual...
01/07/2022
Oncology
Charu Aggarwal, MD
Podcasts
Dr Aggarwal Discusses Plasma-Based NGS for Patients With Nonsquamous NSCLC
11/22/2021
Charu Aggarwal, MD, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.
Charu Aggarwal, MD, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.
Charu Aggarwal, MD, discusses...
11/22/2021
Oncology
Melina Marmarelis, MD, Lova Sun, MD, and Hossein Borghaei, DO
Debates and Roundtables
Expert Roundtable: Melina Marmarelis, MD, and Colleagues Talk Treatment of KRAS G12C NSCLC
11/01/2021
In this virtual roundtable, Dr Marmarelis convened with Lova Sun, MD, and Hossein Borghaei, DO, to discuss the treatment of patients with lung cancer and KRAS G12C sensitive mutations.
In this virtual roundtable, Dr Marmarelis convened with Lova Sun, MD, and Hossein Borghaei, DO, to discuss the treatment of patients with lung cancer and KRAS G12C sensitive mutations.
In this virtual roundtable, Dr...
11/01/2021
Oncology
Edgardo Santos, Luis Raez, Federico Albrecht, Mark Socinski, John Heymach
Debates and Roundtables
Expert Roundtable: The Management and Care of EGFR Patients
10/28/2021
In part three of this virtual roundtable discussion, a panel of experts sat down with Oncology Learning Network to discuss the management and care of EGFR patients.
In part three of this virtual roundtable discussion, a panel of experts sat down with Oncology Learning Network to discuss the management and care of EGFR patients.
In part three of this virtual...
10/28/2021
Oncology

Advertisement

Advertisement

Advertisement

Recent News

FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement